All systems operational
Q3 2025

Serum level of interleukin-11 in patients with rheumatoid arthritis; relation to disease activity and interstitial lung disease

Yomna Yosry Mohamed Abd Elgawad · Enas Aboelkheir Abdelaleem · Noha Abd Elhafeez Abd Elkadr · Hanaa Mohammed Hassan
10.1186/s43166-025-00367-9 386 Views 0 Citations
0
Citations
386
Views
Abstract

Abstract

Background
Rheumatoid arthritis is a complex autoimmune disease characterized by local and systemic inflammation. The purpose of this study was to assess serum level of circulating interleukin-11 in rheumatoid arthritis cases and to estimate its correlation with clinical and laboratory parameters of rheumatoid arthritis disease, especially interstitial lung disease and disease activity.


Methodology
This was a case-control study carried out on sixty rheumatoid arthritis patients who were divided into two groups: thirty rheumatoid arthritis patients without interstitial lung disease and thirty rheumatoid arthritis patients with interstitial lung disease. The patients were classified according to the criteria for rheumatoid arthritis and were recruited from the outpatient and inpatient department of Rheumatology and Rehabilitation between June 2023 to February 2024. Thirty healthy participants were also included as control.


Results

There was a statistically significant higher level of interleukin-11 among rheumatoid arthritis patients, both with interstitial lung disease and non-interstitial lung disease, compared to healthy controls (
P
-value less than 0.001). However, the difference between the interstitial lung disease and non-interstitial lung disease groups was statistically insignificant (p-value greater than 0.05). Similarly, the association between interstitial lung disease type and interleukin-11 level in the interstitial lung disease group was not significant (
P
-value > 0.05). Interleukin-11 levels had a significant role in detecting rheumatoid arthritis (compared to controls) at a cut-off value of 32.7 pg/mL, with a sensitivity of 96.67% and a specificity of 60%, a positive predictive value of 82.4%, and a negative predictive value of 81.8%.



Conclusion
Interleukin-11 is highly elevated in both rheumatoid arthritis without interstitial lung disease and rheumatoid arthritis with interstitial lung disease but did not differentiate between them. This suggests that interleukin-11 is involved in the inflammatory process of both articular and extra-articular manifestations. However, in the absence of a correlation between the disease activity score for the twenty-eight-Joints and interleukin-11, further research is needed to understand its role in etiopathogenesis.

Cite this Article (APA)
Yomna, Y. M. A. E., Enas, A. A., Noha, A. E. A. E., Hanaa, M. H. (2025). Serum level of interleukin-11 in patients with rheumatoid arthritis; relation to disease activity and interstitial lung disease. Egyptian Rheumatology and Rehabilitation. https://doi.org/10.1186/s43166-025-00367-9
Related Papers
Sleep quality, anxiety, depression, and quality of life in rheumatoid arthritis patients and impact …
Maha S. I. Abdelrahman; Ahmad M. Shaddad; Waleed Gamal Elddin Khaleel; Esraa A. · 2024
14
cites
393
Serum malondialdehyde as a marker of oxidative stress in rheumatoid arthritis
Ghada A. Nabih; Nehal EEl Sheshtawy; Dalia M. E. El Mikkawy; Marwa A. Kamel · 2024
13
cites
399
Vitamin D management update: evidence-based guidelines for vitamin D optimization by the Egyptian Ac…
Yasser El Miedany; Mathias Toth; Maha Mohamed El Gaafary; Safaa A. Mahran; Walee · 2025
10
cites
396
TNF-α in the serum and synovial fluid of patients with rheumatoid arthritis: correlation with sonogr…
Aya El Hassany; Samar Tharwat; Mostafa Mansour; Asmaa Farouk Enein · 2024
8
cites
394
Screening to prevent osteoporotic fractures in Egypt: a position statement of the Egyptian Academy o…
Yasser El Miedany; Maha El Gaafary; Naglaa Gadallah; Safaa Mahran; Mohamed Hassa · 2024
7
cites
396
Access
View Full Text via DOI
Published in
ISSN 2090-3235
Quartile Q3
AMS Score 76
Field Medicine & Health Sciences
Publisher Springer (Biomed Central Ltd.)
Country 🇪🇬 Egypt
View Journal Profile →
Authors
Publication Details
Year 2025
Language English
Added 14 Aug 2026